Joan Schwartz releases 'Divine Healing: Ancient Secrets of Our Ancestors'
RIVERTON, Utah, June 11, 2025 /PRNewswire-PRWeb/ -- First-time author Joan Schwartz marks her entry into publishing with the release of "Divine Healing: Ancient Secrets of Our Ancestors" (published by Balboa Press). Blending ancient spiritual insight with contemporary scientific understanding, this book introduces the Integrated Healing Dynamics (IHD) Method — a holistic, accessible healing framework designed to awaken the innate power within every individual.
Rooted in a vision that first appeared to her in 1988, Schwartz says the inspiration for "Divine Healing" came through higher guidance. "I had a revelation and saw the book from beginning to end," she recalls. "Later, I was given direction to write a healing book so that if people couldn't get a session or help from me, they could heal themselves."
"Divine Healing: Ancient Secrets of Our Ancestors" is a complete healer's resource that empowers readers with the knowledge and techniques to realign their energy, awaken their body's natural healing systems, and cultivate peace, joy, and self-love. The IHD Method taught in the book is the culmination of a lifetime of spiritual dialogue and deep intuitive knowing. Through its simple, step-by-step exercises and guiding principles, readers are invited to remove the "mask" that blocks them from their true essence — and step into their divine right to healing.
"Healing is not just about the body; it is about the mind and spirit too," the author reminds. From relieving physical pain to addressing emotional wounds and spiritual imbalances, "Divine Healing: Ancient Secrets of Our Ancestors" offers a practical roadmap to transformation. To get a copy and learn more, visit https://www.balboapress.com/en/bookstore/bookdetails/847934-divine-healing.
"Divine Healing: Ancient Secrets of Our Ancestors" By Joan Schwartz Hardcover | 6 x 9in | 836 pages | ISBN 9798765255186 Softcover | 6 x 9in | 836 pages | ISBN 9798765255162 E-Book | 836 pages | ISBN 9798765255179 Available at Amazon and Barnes & Noble
About the Author Joan Schwartz is a seasoned hypnotherapist and integrative healer with decades of experience in energy work, clinical hypnotherapy, and alternative healing. Her journey began in childhood with a deep sensitivity to unseen energies and was shaped by transformative life events, including a pivotal car accident in 1965 and a near-fatal brain hemorrhage. With a Ph.D. in Alternative Healing, Clinical Hypnotherapy and Philosophy, Schwartz blends science and spirituality to empower others in unlocking their healing potential. She is passionate about helping individuals live peaceful, fulfilling lives through self-discovery and holistic healing practices.
Balboa Press, a division of Hay House, Inc. – a leading provider in publishing products that specialize in self-help and the mind, body, and spirit genres. Through an alliance with the worldwide self-publishing leader Author Solutions, LLC, authors benefit from the leadership of Hay House Publishing and the speed-to-market advantages of the self-publishing model. For more information, visit balboapress.com. To start publishing your book with Balboa Press, call 844-682-1282 today.
Media Contact
Marketing Services, BalboaPress, 844-682-1282, pressreleases@balboapress.com, https://www.balboapress.com/en/bookstore/bookdetails/847934-divine-healing
View original content to download multimedia:https://www.prweb.com/releases/joan-schwartz-releases-divine-healing-ancient-secrets-of-our-ancestors-302478348.html
SOURCE BalboaPress
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
InventHelp Inventor Develops Organic Formula to Reduce Pain (HWT-601)
PITTSBURGH, Aug. 13, 2025 /PRNewswire/ -- "I thought there could be an all-organic formula to assist with pain relief and stiffness in various areas of the body," said an inventor, from Rock Creek, Ohio, "so I invented the PAIN AWAY. My formula works quickly to reduce pain, inflammation, and discomfort." The patent-pending invention provides an all-organic formula to aid in the treatment of pain caused by various ailments such as arthritis, back pain, restless leg syndrome, etc. In doing so, it helps relieve pain and discomfort. It also could increase mobility. The invention features an effective formula that is easy to apply so it is ideal for individuals with arthritis, back pain, etc. The original design was submitted to the National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 24-HWT-601, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at View original content to download multimedia: SOURCE InventHelp
Yahoo
3 hours ago
- Yahoo
Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030
"Driven by urgent unmet needs and scientific advances, the Alzheimer's Disease DMT market is poised for rapid growth as pharmaceutical companies shift their focus to multi-target therapies that address the complex pathology of the disease." BOSTON, Aug. 13, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Disease-Modifying Therapies for Alzheimer's Disease: Global Markets" is projected to reach $13.1 billion by the end of 2030, growing at a CAGR of 67.8% during the forecast period of 2025-2030. The Alzheimer's disease (AD) disease-modifying therapies (DMTs) market is in its early stages, with lecanemab being the first fully approved DMT by the U.S. FDA in July 2023. Several other DMTs in late-stage trials could significantly expand the market if approved. BCC Research forecasts future revenues based on current products and potential candidates. The report analyzes the market by target type (anti-amyloid and emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, and the Middle East and Africa). This report is particularly relevant today because the Alzheimer's disease (AD) DMT market is in its early stage of development, with several therapies currently in late-stage clinical trials. If these therapies are approved, they could significantly expand the market and reshape treatment options. In this context, studying the AD DMTs market is both timely and crucial for pharmaceutical companies and industry stakeholders. The report offers essential market and business insights, helping participants in the AD drugs industry make informed decisions and prepare for upcoming opportunities. The factors driving the market's growth include: High Unmet Need in AD Treatment: Alzheimer's disease currently lacks effective long-term treatments, with existing options only offering temporary symptom relief. This creates a strong demand for therapies that can slow or halt disease progression, encouraging investment, innovation, and regulatory support for disease-modifying therapies. Use of Biomarkers to Accelerate Approvals of AD DMTs: Biomarkers like amyloid-beta and tau proteins help detect Alzheimer's early and track its progression. Their use in clinical trials allows faster and more precise evaluation of new therapies, enabling quicker regulatory approvals and more targeted treatment development. Request a sample copy of the global and regional markets for disease-modifying therapies for Alzheimer's disease report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $235.8 million Market size forecast $13.1 billion Growth rate CAGR of 67.8% for the forecast period of 2025-2030 Segments covered Target Type, Drug Type, Drug Molecule Type, and Region Regions covered North America, Europe, Asia-Pacific, South America, Middle East and Africa Market drivers • High unmet need in AD treatment. • Use of biomarkers to accelerate AD DMTs approval. Interesting facts: As of May 2025, over half of the AD therapeutic candidates in phase 3 trials are disease modifying small molecules ( There are very few DMTs targeting the moderate to advanced stages of AD. Emerging startups: AgeneBio Inc.: The company is investigating AGB101 (levetiracetam) in phase 2 and 3 clinical trials for the treatment of hippocampal overactivity and to assess its ability to control progression to Alzheimer's dementia. Currently, no treatments have shown these benefits. TauRx Pharmaceuticals: TauRx's research centers on tau aggregation inhibitors (TAIs), which aim to prevent or reverse the formation of tau protein tangles in the brain. TRx0237 is a late-stage AD therapeutic candidate. It is an oral tau aggregation inhibitor designed for early intervention to modify the underlying disease process and slow the progression of AD. The report addresses the following questions: What are the projected size and growth rate of the Alzheimer's disease-modifying therapies market?- The global Alzheimer's DMT market was estimated at $235.8 million in 2024. The market is projected to reach $13.1 billion in by the end of 2030, growing at a CAGR of 67.8% during the forecast period. Which market segments are covered in the report?- Target type, drug, molecule type, and region. Which target type will be dominant through 2030?- By target type, the anti-amyloid segment is expected to be the largest market by the end of 2030. Which molecule type market is growing the fastest?- The large molecule segment is the fastest growing market. What are the key challenges in of the market?- Modest clinical benefits, significant risk of side effects, and the high cost of approved DMTs remain challenges to the widespread adoption of these drugs. Market leaders include: ALZHEON INC. ANAVEX LIFE SCIENCES CORP. ANNOVIS BIO INC. BIOGEN BIOVIE INC. EISAI CO. LTD. JOHNSON & JOHNSON LILLY NOVO NORDISK A/S TAURX PHARMACEUTICALS LTD. Related reports: Neurology Market: A BCC Research Overview: This report offers a detailed analysis of the global neurology therapeutics market, segmented by conditions such as Parkinson's, Alzheimer's, epilepsy, autism, psychotic disorders, multiple sclerosis, and brain tumors. It explores drug classes, market dynamics, pipeline developments, competitive landscape, and regional trends across North America, Europe, Asia-Pacific, and the Rest of the World, providing insights into current and future market potential. Alzheimer's Disease Therapeutics and Diagnostics: Global Markets: This report provides an overview of the global Alzheimer's disease diagnostics and therapeutics market, focusing exclusively on biomarker tests for diagnostics and approved pharmacological treatments for therapeutics. It excludes cognitive tests, neuroimaging, procedural interventions, and off-label drug use. The market is segmented by test type, drug class, disease stage, and region, and includes analysis of clinical trials, innovations, and emerging trends. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC
WIRED
3 hours ago
- WIRED
What Is Creatine? The Gym Bro Supplement Is Suddenly Everywhere
It's the most studied supplement in sports medicine, but it's not just for athletes anymore. Courtesy of Amazon; Getty Images; Thorne All products featured on WIRED are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. Learn more. First, it was mushrooms in your coffee. Then protein in your soda. The latest wellness staple sneaking into your pantry is creatine. In the days of yore, creatine supplements were a muscle-bro staple, relegated to the lockers of collegiate linebackers and bodybuilders. Lately, it has muscled its way into Pilates studios, gym girlies' TikToks, and longevity wellness retreats. This content can also be viewed on the site it originates from. 'Creatine has been gaining popularity among women across different age groups,' says Gretchen Zimmermann, a registered dietitian. 'We do see women who are lifting heavier, and there used to be this thing that was circulating a decade or two ago, where women thought that if they lifted heavy, they would get bulked up. Now we know that's not true, and naturally there's some interest in creatine for that reason.' But what is creatine? Here's everything you need to know. Creatine is a compound your body produces in the liver, kidneys, and pancreas, according to Federica Amati, a medical scientist and registered public health nutritionist. Most of it ends up in your skeletal muscles, where it's stored as phosphocreatine and used to regenerate adenosine triphosphate (ATP), the molecule that powers muscle contractions, nerve signals, and protein synthesis for tissue repair. The rest—less than 5 percent—is found in brain tissue and the testes. You make about a gram of creatine a day from three amino acids: arginine, glycine, and methionine. You also get more from animal-based foods like red meat, fish, and poultry. For most healthy people, that's enough. So, creatine supplements aren't essential for general health, but they can boost performance and recovery under the right conditions. Photo by Steve Mitchell/EMPICS via Getty Images ATP is your cells' main energy source. High-intensity exercise drains it fast, breaking ATP down into adenosine diphosphate (ADP). Creatine phosphate donates a phosphate group to ADP, recycling it back into ATP almost immediately. The more phosphocreatine stored in your muscles, the faster you can regenerate ATP and the more power you can produce in short bursts. Creatine is most useful for activities that demand short, intense effort: sprinting, weightlifting, and high-intensity interval training, to name a few. It's far less relevant for endurance sports like marathons. Some evidence suggests creatine also increases muscle glycogen storage, which could help with recovery and energy replenishment between sessions. Creatine doesn't directly build muscle, but paired with resistance training and adequate nutrition, it can help preserve muscle strength and lean body mass. It's particularly important if you're recovering from an injury, or as you age, when sarcopenia (age-related muscle loss) becomes a risk, as it activates specialized stem cells known as satellite cells. Zimmerman points out that women, especially in perimenopause and menopause, may see health benefits. 'As women get older—starting in our forties—we lose body mass 1 to 2 percent a year, and that can affect bone health later on in life,' says Zimmermann. 'Creatine [supplements] support keeping and building lean muscle mass.' Zimmermann adds, 'Women tend to have lower muscle mass than men, just naturally, so I think women may actually respond better to supplementation, because they're at baseline.' While the effects of creatine supplementation on athletic performance are well-documented, its effects on mental performance are still emerging. Early findings are promising. Studies suggest it may reduce mental fatigue, especially during high-stress situations, such as sleep deprivation or exhaustive exercise. It may also improve certain aspects of memory, particularly in groups with lower baseline creatine levels, such as vegetarians and older adults. Some preliminary research even suggests it could help with symptoms of depression by supporting brain energy and boosting the production of feel-good neurotransmitters like dopamine and serotonin. That's particularly relevant for women experiencing perimenopause and menopause, says Zimmerman. 'Estrogen shifts affect brain health, our mood, brain fog, and being able to think clearly.' Nowadays, step into any GNC and you'll find several forms of creatine: creatine hydrochloride, magnesium creatine chelate, creatine citrate, creatine nitrate, creatine ethyl ester, and buffered creatine. But creatine monohydrate is the most studied, the most effective, and usually the cheapest, according to the International Society of Sports Nutrition. No other form has shown any additional benefits, confirms Amati. Creatine monohydrate is typically sold as a flavorless, white powder that you can mix into water or a shake. The standard dose is three to five grams per day, says Amati. Some athletes may 'load' with higher doses, but studies show this offers no long-term benefits and can put unnecessary stress on the kidneys, says Amati. For most healthy adults, creatine is a safe and well-tolerated supplement for months or even years of use. Short-term and long-term clinical trials have found no significant health risks. The main side effects are minor: weight gain from temporary water retention in the first week of supplementation, bloating, and mild gastric discomfort, usually from oversize doses. However, there are a few considerations to keep in mind: AccordionItemContainerButton We're currently testing Thorne Creatine. Power up with unlimited access to WIRED. Get best-in-class reporting and exclusive subscriber content that's too important to ignore. Subscribe Today.
